Incannex Healthcare (IXHL) Share-based Compensation (2023 - 2026)
Incannex Healthcare (IXHL) posted quarterly Share-based Compensation of -$1.5 million for Q1 2026, down 252.88% year-on-year from $960201.3 in Q1 2025, and up 35.59% on a QoQ basis from -$2.3 million in Q4 2025.
Incannex Healthcare (IXHL) Share-based Compensation (2023 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Share-based Compensation for 4 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.
- Quarterly Share-based Compensation fell 252.88% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $177000.0 (down 94.0% YoY) and the FY2025 annual result came in at $2.6 million, down 97.71% from the prior year.
- Share-based Compensation improved to -$1.5 million in Q1 2026 per IXHL's latest filing, from -$2.3 million in the prior quarter.
- Over the last five years, Share-based Compensation for IXHL reached as high as $3.4 million in Q4 2023 and fell as low as -$2.3 million in Q4 2025.
- A 4-year average of $725307.7 and a median of $459000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation soared 5764.91% — and 2025, when it sank 423.91%.
- Year by year, Share-based Compensation stood at $3.4 million in 2023, then plunged by 112.81% to -$435000.0 in 2024, then plunged by 423.91% to -$2.3 million in 2025, then jumped by 35.59% to -$1.5 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered -$1.5 million, -$2.3 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Incannex Healthcare | 3.63 Mn | 3.63 Mn | - | -1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.47 Mn |
| Mar 31, 2026 | -1.47 Mn |
| Dec 31, 2025 | -2.28 Mn |
| Dec 31, 2025 | -2.28 Mn |
| Sep 30, 2025 | 2.63 Mn |
| Sep 30, 2025 | 2.63 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | -416,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Dec 31, 2024 | -435,000.00 |
| Dec 31, 2024 | -435,000.00 |
| Sep 30, 2024 | 459,000.00 |
| Sep 30, 2024 | 459,000.00 |
| Jun 30, 2024 | 3.34 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 3.40 Mn |
| Dec 31, 2023 | 3.40 Mn |